What Researchers Did
Researchers conducted a randomized prospective study comparing pharmacological treatment alone versus pharmacological treatment combined with hyperbaric oxygen therapy for idiopathic sudden sensorineural hearing loss.
What They Found
The overall success rate, defined as a pure tone audiometry gain larger than 15 dBHL, was significantly higher in the HBO+P group at 60.6% (40/66) compared to the P group at 42.9% (30/70) (p < 0.05). Subgroup analysis showed that patients with mild-moderate baseline hearing loss, aged 50 or younger, treated within 14 days, or without dizziness, particularly benefited from the additional HBO therapy.
What This Means for Canadian Patients
Canadian patients experiencing idiopathic sudden sensorineural hearing loss may achieve better hearing recovery if hyperbaric oxygen therapy is added to their standard pharmacological treatment. This combined approach could be particularly beneficial for those with mild-moderate hearing loss, younger age, early treatment initiation, or absence of dizziness.
Canadian Relevance
This study was not conducted in Canada and therefore its direct relevance to the Canadian healthcare system or patient population is not immediately clear.
Study Limitations
The study's generalizability may be limited as it was conducted at a single center, and the abstract does not specify the long-term follow-up of the participants.